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We tried to determine whether high-resolution computed tomography (HRCT) patterns
correlate with the immunopathogenetic findings and whether they could provide helpful
information for predicting the outcomes in non-neoplastic drug-induced pneumonitis. The
HRCT images were classified as most suggestive of pneumonitis, diffuse alveolar damage
(DAD), non-specific interstitial pneumonia, organizing pneumonia (OP), hypersensitivity
pneumonitis, and acute eosinophilic pneumonia (AEP) in 34 patients with non-neoplastic
drug-induced pneumonitis. The patients were analyzed for the bronchoalveolar lavage
(BAL) cell findings and for the circulating levels of interferon-inducible protein 10 (IP-10)
and macrophage-derived chemokine (MDC), which were measured by an enzyme-linked
immunosorbent assay. The cumulative dose of corticosteroids received by the patients and
the day when they required supplemental oxygen were calculated as outcome markers.
There were no differences in the circulating chemokine levels and the BAL cell profiles
except for the eosinophil percentages among the HRCT patterns. Most of the cases with
pulmonary eosinophilia belonged to the OP and AEP groups, and the circulating MDC levels
correlated with BAL eosinophil percentages. We could not find any relationship between
the BAL cell profiles or the chemokine levels and the outcome markers. In contrast, the
HRCT patterns rather predicted the outcomes because larger cumulative dose of steroids
and longer oxygen supply were required for the patients in the DAD and OP groups. InElsevier Ltd. All rights reserved.
586 5814; fax: +81 97 586 6502.
u.ac.jp (E. Miyazaki).
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HRCT and immunopathogenesis in drug-induced pneumonitis 893contrast, all patients with AEP recovered without steroid administration. The present
study suggests that HRCT does not predict cellular pathophysiology but it may predict the
corticosteroid use in non-neoplastic drug-induced pneumonitis.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Although the high-resolution computed tomography (HRCT)
findings of lung disease are often non-specific, there are
some characteristic HRCT findings for some lung diseases
which are based on the pathologic findings.1–3 Especially in
idiopathic interstitial pneumonias (IIPs), which consist of
seven histologically distinct subtypes, the HRCT findings
reflect the histological patterns, thus predicting the prog-
nosis and determining the most appropriate interven-
tion.1,4–6 The HRCT classification based on the evidence
from IIPs and other diffuse lung diseases could be applied to
drug-induced pneumonitis.7–13 However, the utility of HRCT
for predicting the outcome in drug-induced pneumonitis is
still controversial. Cleverley et al.9 reported that the HRCT
was of limited value in predicting the histological patterns
and prognosis when they examined 20 cases of drug-induced
lung disease including 15 cases of neoplastic drug-induced
pneumonitis. Another report showed that the HRCT pattern
could predict the prognosis in gefitinib-induced pneumoni-
tis, gefitinib being, is a selective inhibitor of the epidermal
growth factor receptor tyrosine kinase.14
Unlike the pathogenesis of neoplastic drug-induced lung
injury in which direct cytotoxic mechanisms are often
involved,15 the immune-mediated mechanisms, particularly
the T lymphocyte-mediated specific inflammation induced
by causative agents appear to contribute to the pathogen-
esis of non-neoplastic drug-induced pneumonitis.16 In such
cases, the different types of immune responses may produce
the different histological phenotypes, which may also be
reflected by the HRCT patterns. In general, the chemokine
predominantly attracting T helper type 1 (Th1) or T helper
type 2 (Th2) cells participate in generating a specific
inflammation.17–20 The Th1 response is crucial for the
granulomatous responses17 and hypersensitivity pneumoni-
tis,18 whereas elevated Th2 chemokines levels are found in
eosinophilic pneumonia.19,20 The Th1 chemoattractant,
interferon-IP-10, and the Th2 chemoattractant, macro-
phage-derived chemokine (MDC) are detected in the
immune-mediated lung diseases and reflect a Th1/Th2
polarization in the lungs.17,18,20 However, there have so far
only been a few reports measuring Th1/Th2-associated
chemokines as they related to the mechanisms of drug-
induced pneumonitis.21
The aim of this study was to clarify the relationship
between the HRCT patterns and the immunopathogenetic
findings, such as the bronchoalveolar lavage (BAL) cell
profiles and circulating chemokine levels in non-neoplastic
drug-induced pneumonitis. We also tried to examine
whether the HRCT patterns or the immunopathogenetic
findings would be helpful for predicting the outcome as
assessed by the cumulative dose of corticosteroids and the
duration when the patient was under oxygen inhalation.Materials and methods
Patient selection and sample retrieval
This study was retrospectively done under IRB approval and
included 34 consecutive patients with non-neoplastic drug-
induced pneumonitis encountered at the Oita University
Hospital during the period between January 1996 and July
2007. The diagnosis of drug-induced pneumonitis was made
according to a method for estimating the probability of drug
reactions by Naranjo et al.,22 and thus 14 definite cases and
20 probable cases were included.HRCT scanning method
All patients underwent chest HRCT scanning. The CT scans
were obtained with a window setting for lung parenchyma
(window width, 1600–1800HU; window level, 600 to
700HU) and mediastinum (window width, 300–350HU;
window level, 25–40HU).
The HRCT images of drug-induced ILD were classified into
the following five patterns. The diffuse alveolar damage
(DAD) pattern was defined as a pattern of extensive bilateral
ground-glass attenuation or consolidations with traction
bronchiectasis, such as in acute interstitial pneumonia.7,9,23
The organizing pneumonia (OP) pattern was defined as a
pattern of multifocal areas of air-space consolidation in a
predominantly subpleural or peribronchial distribution, such
as in cryptogenic OP or chronic eosinophilic pneumonia,7,9,12
and the hypersensitivity pneumonitis (HP) pattern was
defined as a pattern of only non-specific area of ground-
glass attenuation without any structural distortion.7,24 The
acute eosinophilic pneumonia (AEP) pattern was defined as a
pattern of patchy distribution of areas of ground-glass
attenuation accompanied by interlobular septal thickening
and pleural effusion.12,13 The non-specific interstitial
pneumonia (NSIP) pattern was defined as a pattern of
bilateral linear opacities, such as in idiopathic NSIP.7,9
Following the initial independent evaluation by three
observers, the HRCT patterns were determined based on
the agreement of at least two observers.BAL cell profiles
The time intervals between the BAL and the HRCT study
were 0–2 days. After informed consent was obtained from
the subjects, we performed BAL and analyzed total
cell concentration and cell differentiation as described
previously.19
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Blood samples were obtained from clotted blood following
centrifugation at 1500g at 4 1C for 10min, and then were
stored at 80 1C until the measurements were performed.
The concentrations of MDC and IP-10 were measured using
an enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems Inc., Minneapolis, MN, USA). The lower limits of
detection for MDC and IP-10 were 62.5 and 1.7 pg/ml,
respectively. The levels of KL-6 were measured by a
sandwich-type electrochemiluminescence immunoassay kit
(Picolumi KL-6; Sanko Junyaku, Tokyo, Japan).
Statistical analysis
The results are presented as median values, with minimum
and maximum values as the range. The Kruskal–Wallis test
was used to compare the values of the different groups. In
cases of a significant difference between the groups, the
intergroup comparisons were assessed by the non-para-
metric methods using the Mann–Whitney U test.
The Pearson’s correlation coefficient was used to deter-
mine any correlations between the variables. Probability
values of o0.05 were regarded as significant.
Results
Patient characteristics and clinical parameters
Thirty-four patients consisted of 20 men and 14 women. The
average age was 64 years (range, 26–82 years). The causalFigure 1 Representative high-resolution computed tomography
(b) non-specific interstitial pneumonia (NSIP) pattern, (c) hyperse
(OP) pattern, and (e) acute eosinophilic pneumonia (AEP) pattern.agents were 9 antibiotics, 7 non-steroidal anti-inflammatory
drugs, 6 Chinese medicines, 4 anti-rheumatic drugs, 2 anti-
arrhythmic drugs and others. The median value of the
PaO2/FIO2 ratio (P/F ratio) was 296 (range, 120–445).
Fifteen patients were treated with pulsed methylpredniso-
lone followed by oral corticosteroid, 8 with oral corticoster-
oid, and 2 with pulsed methylprednisolone. No steroids
were given to 11 patients who recovered spontaneously by
discontinuing the causative drugs. No individuals experi-
enced death during the course of this study.
The chest HRCT patterns
The representative HRCT patterns are shown in Figure 1.
The DAD pattern was determined in 6 patients, the NSIP
pattern in 5 patients, the HP pattern in 7 patients, the OP
pattern in 10 patients, and the AEP pattern in 6 patients.
The categories of the causal agents showed no particular
relationship with the HRCT patterns.
We examined whether the HRCT patterns would reflect
the disease severity and the outcome. The DAD group had a
significantly lower P/F value (median, 198; range, 120–280),
as compared with that of the NSIP group (median, 293;
range, 258–439), the HP group (median, 292; range,
225–339), the OP group (median, 318; range, 240–445),
and the AEP group (median, 293; range, 213–357)
(Figure 2A). For the quantitative assessment, the cumula-
tive doses of steroids received by the patients were
expressed following conversion to prednisolone dose.
Among each group, the DAD group required the largest
cumulative amount of corticosteroid (median, 5240mg;(HRCT) patterns: (a) diffuse alveolar damage (DAD) pattern,
nsitivity pneumonitis (HP) pattern, (d) organizing pneumonia
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HRCT and immunopathogenesis in drug-induced pneumonitis 895range, 1000–9195mg), which was higher as compared with
the NSIP group (median, 264mg; range, 0–735mg), the HP
group (median, 415mg; range, 0–4470mg) and the OP group
(median, 2722mg; range, 0–7835mg) (Figure 2B) and the
AEP group. None of the 6 patients in the AEP group received
steroid treatment. We also examined every HRCT finding
in association with the cumulative steroid doses. As a
consequence, the patients with air-space consolidation on
HRCT required a larger amount of steroid (Figure 3A).
The cumulative doses of corticosteroids correlated
negatively with the P/F ratios (Figure 3B), thus indicating
the steroid doses to be prescribed by the disease severity at
the initial presentation. We therefore calculated how long
the patients required oxygen therapy, which also reflected
long-term outcome, thus resulting in a similar tendency to
that of the cumulative doses of steroids. When examined in
all patients, the days under oxygen therapy correlated well
with the cumulative doses of steroids (Figure 3C).BAL cell profiles
We summarized the BAL cell profile in each group of HRCT
pattern in Table 1. It was interesting to note that the DAD
group exhibited a similar BAL cell profile as the 4 other
groups; increased percentages of lymphocyte in all cases
and increased eosinophil levels in 2 cases, thus suggesting
immune-mediated mechanisms. Among the different groups
of the HRCT patterns, there were no differences in the total
cell concentrations and in the percentages of lymphocyte
and neutrophil. Prominent BAL eosinophilia (eosinophils
420%) was observed in 10 cases, most of which belonged
to the groups with the OP and the AEP patterns. In another
expression, 5 of 10 patients in the OP group and 4 of 6
patients in the AEP group had BAL eosinophilia. We did not
find any case with prominent eosinophilia in the NSIP and HP
groups.
The percentages and numbers of eosinophil as well as
lymphocytes or neutrophils did not correlate with the P/F
ratios, the cumulative steroid doses, the days under oxygen
therapy, or the circulating KL-6 levels.St
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K. Takatani et al.896The KL-6 and the circulating chemokine levels
We employed serum KL-6 as a marker of alveolar epithelial
cell damage and the KL-6 value is shown in Table 1. The
serum KL-6 of DAD and NSIP groups tended to be high and
when the cut-off value was determined to be 500U/ml, the
KL-6 positive ratios were varied among the HRCT groups with
83% in DAD, 75% in NSIP, 43% in HP, 30% in OP, and 17% in the
AEP group. The KL-6 levels did not correlate with the
cumulative steroid doses or the days under oxygen therapy.
We examined an association between the circulating
chemokines levels and the HRCT patterns (Table 1). The
circulating levels of IP-10 and MDC of the disease group were
significantly higher when compared with those of age-
matched healthy volunteers (HV). The circulating IP-10
levels were preferentially high in the DAD, HP, and OP groups
although they were not statistically significant among the
HRCT groups. We did not find any correlation between the
serum IP-10 levels and the clinical parameters including the
P/F ratio, cumulative dose of steroid, the circulating KL-6
level or BAL cell profile.
The MDC levels tended to be high in the OP group, 50% of
which exhibited pulmonary eosinophilia. Interestingly, we
found a positive correlation between the circulating MDC
level and the eosinophil percentages in the BAL fluids, but
not in the serum (Figure 4). The circulating MDC levels did
not correlate with the P/F ratio, the steroid cumulative
dose, or the KL-6 level.Discussion
We hypothesized that the HRCT patterns may be associated
with cellular pathophysiology in the inflamed lungs and
chemokine expression patterns in non-neoplastic drug-
induced pneumonitis. As a consequence, our study only
disclosed the fact that the pulmonary eosinophilia waseosinophil in bronchoalveolar lavage (BAL) fluid.
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have a similar cellular pathophysiology as shown previously
by Silva and Mu¨ller.25 It was common that the patients
demonstrating the same HRCT pattern had different BAL cell
profiles and chemokine expressions, indicating that HRCT
does not precisely predict the cellular pathophysiology in
drug-induced pneumonitis.
There have so far been few studies performed regarding
the chemokine levels in drug-induced pneumonitis. We
found increased serum levels of Th1 chemokine IP-10 and
Th2 chemokine MDC in the patients; however, there were no
uniform trends toward Th1 or Th2 polarization among the
different HRCT groups. A recent paper suggests that
elevated serum IP-10 might be involved in drug-induced
DAD21; however, the present study disclosed that this
phenomenon of the IP-10 elevation was not specific for the
DAD pattern. Moreover, unlikely to previous studies showing
the circulating levels of IP-10 to correlate with the severity
of Th1-associated diseases,26–28 the serum IP-10 levels did
not correlate with the disease severity or the outcome
assessed by the P/F ratios, the cumulative steroid doses, or
the days under oxygen therapy in our patients with non-
neoplastic drug-induced pneumonitis. The results of corre-
lation with the disease severity or the outcome were similar
in the serum MDC levels. As an interesting finding, the
present study showed a positive correlation between the
serum MDC levels and pulmonary eosinophilia regardless of
the HRCT findings. This indicates that the serum MDC levels
could therefore be more useful to predict BAL eosinophilia
than did the HRCT.
In this series, six patients were determined to have the
AEP pattern on HRCT. In four patients, the BAL harvested
numerous eosinophils greater than 20%, whereas we could
not obtain the evidence of pulmonary eosinophilia from the
other two patients. These results prove that different
immunological mechanisms produce similar HRCT patterns.
Importantly, however, all six cases showed homogeneous
outcomes revealing spontaneous improvement without
steroid therapy. This suggests that the AEP pattern in HRCT
is self-limited regardless of the presence of pulmonary
eosinophilia.
Given that the immunopathogenetic findings did not
predict the disease severity or clinical outcome, we then
explored whether the HRCT pattern would predict the
degree of hypoxemia, the steroid requirement and pro-
longed clinical course. We adopted the cumulative doses of
steroid and the days under oxygen therapy as clinical
outcome markers because no death was observed among
our patients. We also measured the serum KL-6, which
reflects alveolar epithelial cell damage29 and correlates
with the extent of lung injury in drug-induced pneumonitis.7
In this regard, the DAD pattern referred to the most severe
injury of the lung parenchyma because of lower P/F ratios
and higher steroid cumulative doses and prolonged oxygen
supply received by the patients, which is consistent with the
previous observation.9–11 However, unlike to the previous
reports for neoplastic drug-induced pneumonitis,9–11,30
death was not observed during the course of our DAD
patients. This indicates that there may be some substantial
differences in the immunological or pathological features
between neoplastic and non-neoplastic drug-induced pneu-
monitis. We analyzed the BAL cell profiles in our patientswith non-neoplastic drug-induced DAD, which disclosed an
increased percentage of lymphocytes in all cases and
increased eosinophil levels in two cases. Moreover, the
patients had elevated levels of IP-10 in their sera. These
results suggest immune-mediated mechanisms in our DAD
patients.
In general, patients with OP can easily achieve a
complete recovery after corticosteroid therapy.4,5 In this
series of non-neoplastic drug-induced pneumonitis, the
cumulative doses of steroids received by the patients with
OP were comparable to those with DAD. The results may be
explained by the association between larger cumulative
doses of steroids and the presence of air-space consolidation
on the HRCT scans. Alternatively, because DAD and OP often
shares similar chest HRCT findings such as areas with ground-
glass attenuation, air-space consolidation and architectural
distortion,31 it might occasionally be difficult to differenti-
ate between DAD and OP. Although the different levels of
serum MDC and KL-6 between the two groups probably
indicate a distinct immunopathogenesis in the two groups,
and we thus expected a large amount of steroids to be
required when air-space consolidation is found.
This study has several limitations. First, most of our
patients are probable cases. In order to give a definite
diagnosis, symptom re-appearance by re-administration
should be proved22; however, a re-challenge test is not always
acceptable in our country. All cases enrolled in this study were
carefully examined for other etiologies to cause acute lung
injury, especially infectious causes by using BAL fluids. When
there were some doubts regarding the diagnosis, then such
cases were excluded. Second, this was retrospectively done in
a single institution to study relatively small number of cases.
To resolve the problem, a prospective and multi-center work
should be conducted in the future.
In conclusion, we herein showed that HRCT did not
precisely predict cellular pathophysiology. The circulating
MDC levels correlate with BAL eosinophilia regardless of the
HRCT findings. We also demonstrated that an assessment of
the HRCT patterns was more beneficial for predicting the
disease severity and cumulative steroid dose required to
cure lung disease than was a measurement of the immuno-
pathogenetic findings, such as the BAL cell profiles or
circulating chemokine levels. The presence of air-space
consolidation in the DAD and OP patterns as well as lower P/
F ratios may let the clinicians expect larger amount of
steroid use and prolonged oxygen supply in cases of non-
neoplastic drug-induced pneumonitis.
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